Brief: Apogee Therapeutics Announces Positive Interim Results From Phase 1B Trial Of Apg808

Apogee Therapeutics

12/05/2025 12:08

May 12 (Reuters) - Apogee Therapeutics Inc APGE.O:

APOGEE THERAPEUTICS ANNOUNCES POSITIVE INTERIM RESULTS FROM THE PHASE 1B TRIAL OF APG808, ITS NOVEL HALF-LIFE EXTENDED IL-4RΑ ANTIBODY, IN PATIENTS WITH MILD-TO-MODERATE ASTHMA

APOGEE THERAPEUTICS INC: APG808 WAS WELL TOLERATED WITH A FAVORABLE SAFETY PROFILE CONSISTENT WITH ANTI-IL-4RΑ CLASS

APOGEE THERAPEUTICS: APG808 SHOWED POTENTIAL FOR DURABLE DISEASE CONTROL IN ASTHMA WITH SUSTAINED FENO DECREASE FROM BASELINE OF 50% AT 12 WEEKS

Source text: ID:nGNX7lm1wq

Further company coverage: APGE.O

 ((Reuters.Briefs@thomsonreuters.com;))